Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled “Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions” (Appl ...

文章核心观点 Renovaro起诉Predictive Oncology违反合并协议 寻求法律救济以维护自身权益和股东利益 诉讼将在2025年加速审理 [1][4] 分组1：诉讼基本信息 - Renovaro于2025年5月9日在特拉华州衡平法院起诉Predictive Oncology 寻求执行2025年1月1日签订的具有约束力的合并协议 2025年获加速审理裁决 [1] - 诉讼寻求特定履行、禁令救济以及因被告违约造成的损害赔偿 案件编号为2025 - 0509 [4] 分组2：合并协议情况 - 两家公司达成具有法律约束力的信函协议 Predictive Oncology将并入Renovaro 以换取新设立的一类优先股 [2] - 2025年1月6日POAI提交8 - K表格公开披露协议后 其股价上涨超50% [2] 分组3：违约情况 - Renovaro称Predictive Oncology于2025年2月19日进行54.5万美元的证券公开发行 违反协议排他性和诚信谈判条款 [3] - 2025年4月3日 Predictive Oncology单方面试图终止协议 且未切实参与最终合并协议的谈判 [3] 分组4：公司情况 - Renovaro旨在通过人工智能和生物技术平台加速精准和个性化长寿医学 涵盖RenovaroBio、RenovaroCube和BioSymetrics等业务 [5]

LOS ANGELES, May 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced that it has received a ruling to expedite a trial in 2025 for the lawsuit it filed on May 9, 2025, in the Delaware Court of Chancery against Predictive Oncology Inc. (NASDAQ: POAI), seeking to enforce a binding merger agreement executed on January 1, 2025. According to the Verified Complaint, the compan ...

U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Renovaro Inc. (Exact name of registrant as specified in its charter) Delaware 45-2259340 (State or other jurisdiction of (I. ...

New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it has launched Augusta, a Precision Neurology Platform for patient stratification, biomarker discovery, drug discover ...

文章核心观点 Renovaro与阿姆斯特丹大学医学中心达成独家合作协议，共同评估和开发血小板RNA诊断技术，有望推动疾病检测和监测新方法的临床验证与发展 [1] 合作内容 - 聚焦评估血小板RNA特征作为生物标志物的临床效用，利用Renovaro的AI/ML能力和与Nebul协议提供的计算资源，从血样中发现疾病信号，转变多种癌症的诊断和预后方法 [2] - 双方将共同优化预测性能，实现高度临床准确性，项目涉及血样收集分析、多模态数据整合和深度学习模型开发 [3] 合作安排 - 双方承诺共同管理合作产生的知识产权，并计划在荷兰成立专门公司，进一步开发和商业化诊断技术 [4] - 合作初始期限为四年，可经双方同意延期 [5] 合作方介绍 - 阿姆斯特丹大学医学中心是领先医疗中心，集高质量患者护理、科研和教育于一体，超16000人在两个地点协作，专注疾病预防和复杂罕见病治疗 [6] - Renovaro旨在通过AI和生物技术平台加速精准和个性化医疗，旗下有RenovaroBio、RenovaroCube和BioSymetrics等公司 [7] 联系方式 - 投资者关系联系Chris Tyson，电话949 - 491 - 8235，邮箱RENB@mzgroup.us，网址www.mzgroup.us [10] - 媒体咨询联系karen@renovarocube.com [10]

LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ:RENB), an AI-driven precision Medicine Company that leverages AI platforms to improve outcomes for cancer and neurologically challenged patients, today announced is expanding our ongoing strategic collaboration with Nebul (www.nebul.com), a leading AI cloud infrastructure company, to advance the early detection of cancer and other diseases. The partnership aims to leverage Renovaro's deep learning and ML programs with Nebul's high-perform ...

Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and Neurology LOS ANGELES, April 09, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced it closed its previously announced merger transaction with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and precision ne ...

文章核心观点 Renovaro Biosciences与Predictive Oncology原计划整合AI/ML平台技术等资源 但Predictive Oncology终止合并交易 Renovaro认为其违约并将寻求赔偿 [1][2] 合作情况 - Renovaro与Predictive Oncology签订有约束力的合并协议 并于2025年2月28日补充延期协议 [2] - 2025年4月3日 Renovaro收到Predictive Oncology终止合并交易的邮件 [2] - Renovaro要求Predictive Oncology遵守协议并签订独家许可协议 否则将寻求法律补救措施 [2] 公司介绍 - Renovaro旨在通过AI和生物技术平台加速精准和个性化医疗 用于早期诊断、靶向治疗和药物发现 [3] - Renovaro旗下包括先进细胞基因免疫治疗公司RenovaroBio和利用AI进行多组学诊断和药物开发的RenovaroCube [3] 联系方式 - 投资者关系联系Chris Tyson 电话949 - 491 - 8235 邮箱RENB@mzgroup.us 网址www.mzgroup.us [5] - 媒体咨询联系karen@renovarocube.com [5]

Company Commits the First Tranche of Financing to Initiate the Integration of AI/ML Platform Technologies, Core Laboratory Capabilities and Business Development Efforts in Europe and the United States Renovaro’s Strategic Acquisition of BioSymetrics Vastly Expands Biomarker and Drug Discovery Opportunities and the Development of Diagnostic Applications in Oncology LOS ANGELES, March 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics ...